Volume 34, No. 4, page 1539: Lines 19-23, left column, should read:
In the ongoing phase IIIb AvaALL trial, bevacizumab is used as maintenance therapy after disease progression. Expected results showed an OS beyond PD of 10.1 months in the experimental arm, receiving bevacizumab plus a second-line agent between pemetrexed, docetaxel or erlotinib, versus 7.9 months in the control arm, receiving only the second-line agent chosen by the investigator (43).
- Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved